Angiotensin Converting Enzyme 2 News and Research

RSS
Study investigates SARS-CoV-2 escape from nirmatrelvir

Study investigates SARS-CoV-2 escape from nirmatrelvir

10 Jun 2022
Association of neuronal and non-neuronal GABA with neuropsychiatric illness in COVID-19 patients

Association of neuronal and non-neuronal GABA with neuropsychiatric illness in COVID-19 patients

10 Jun 2022
Gastrointestinal complications caused by SARS-CoV-2

Gastrointestinal complications caused by SARS-CoV-2

7 Jun 2022
De novo-designed mini-protein against SARS-CoV-2

De novo-designed mini-protein against SARS-CoV-2

7 Jun 2022
Omicron lineage spike proteins use ACE2 receptors more efficiently

Omicron lineage spike proteins use ACE2 receptors more efficiently

7 Jun 2022
Link between COVID-19 severity and microbiome of saliva and nasopharynx

Link between COVID-19 severity and microbiome of saliva and nasopharynx

6 Jun 2022
Safety and efficacy of SCB-2019 COVID vaccine candidate as a ChAdOx1-S booster

Safety and efficacy of SCB-2019 COVID vaccine candidate as a ChAdOx1-S booster

6 Jun 2022
The effects of accessory protein mutations and other non-spike mutations on SARS-CoV-2 pathogenesis

The effects of accessory protein mutations and other non-spike mutations on SARS-CoV-2 pathogenesis

2 Jun 2022
Inverse relationship identified between SARS-CoV-2 and influenza infections

Inverse relationship identified between SARS-CoV-2 and influenza infections

1 Jun 2022
Study shows the SARS-CoV-2 accessory protein ORF7a inhibits HLA-I surface expression levels in human cells

Study shows the SARS-CoV-2 accessory protein ORF7a inhibits HLA-I surface expression levels in human cells

1 Jun 2022
The pineapple-derived jacalin-related lectin as a potential anti-SARS-CoV-2 agent

The pineapple-derived jacalin-related lectin as a potential anti-SARS-CoV-2 agent

31 May 2022
Evaluating tixagevimab plus cilgavimab against SARS-CoV-2

Evaluating tixagevimab plus cilgavimab against SARS-CoV-2

30 May 2022
Researchers identify a human monoclonal antibody that could broadly neutralize several variants of SARS-CoV-2, SARS-CoV, and other coronaviruses

Researchers identify a human monoclonal antibody that could broadly neutralize several variants of SARS-CoV-2, SARS-CoV, and other coronaviruses

30 May 2022
Exploring virological profiles of recently emerged SARS-CoV-2 Omicron variants

Exploring virological profiles of recently emerged SARS-CoV-2 Omicron variants

30 May 2022
Continuous evolution of SARS-CoV-2 Omicron variant yielding immune evasive subvariants

Continuous evolution of SARS-CoV-2 Omicron variant yielding immune evasive subvariants

30 May 2022
Study finds long-term exposure to common air pollutants is associated with COVID-19 severity

Study finds long-term exposure to common air pollutants is associated with COVID-19 severity

30 May 2022
Scientists determine trajectory and pathophysiology of post-COVID-19 syndrome

Scientists determine trajectory and pathophysiology of post-COVID-19 syndrome

30 May 2022
A polymer-nanoparticle hydrogel to subcutaneously deliver broadly neutralizing antibodies against SARS-CoV-2

A polymer-nanoparticle hydrogel to subcutaneously deliver broadly neutralizing antibodies against SARS-CoV-2

27 May 2022
Cell membrane-bound enzyme is essential for SARS-CoV-2 infectivity, study shows

Cell membrane-bound enzyme is essential for SARS-CoV-2 infectivity, study shows

26 May 2022
Researchers report novel interactions between the SARS-CoV-2 S protein and estrogen receptor alpha

Researchers report novel interactions between the SARS-CoV-2 S protein and estrogen receptor alpha

26 May 2022

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback